| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 114.090 | 560.196 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -27 |
| Total Expenses - EUR | 1.212.555 | 2.058 | 102 | 9 | 12 | 47 | 14 | 16 | 0 | 918.600 |
| Gross Profit/Loss - EUR | -1.098.465 | 558.138 | -102 | -9 | -12 | -47 | -14 | -16 | 0 | -918.627 |
| Net Profit/Loss - EUR | -1.098.465 | 558.138 | -102 | -9 | -12 | -47 | -14 | -16 | 0 | -918.627 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Varium Parafarmaceutice Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 1.891.347 | 1.757.675 | 1.727.877 | 1.685.733 | 1.653.087 | 1.621.748 | 1.585.784 | 1.590.704 | 1.585.881 | -187 |
| Inventories | 260.846 | 243.711 | 340 | 334 | 328 | 321 | 314 | 315 | 314 | 0 |
| Receivables | 1.627.218 | 1.510.670 | 1.724.358 | 1.682.278 | 1.649.698 | 1.618.424 | 1.582.534 | 1.587.444 | 1.582.630 | -187 |
| Cash | 3.283 | 3.294 | 3.179 | 3.121 | 3.061 | 3.003 | 2.936 | 2.945 | 2.936 | 0 |
| Shareholders Funds | -2.219.004 | -1.638.235 | -1.610.616 | -1.581.067 | -1.550.460 | -1.521.113 | -1.487.395 | -1.492.026 | -1.487.502 | -2.397.815 |
| Social Capital | 2.250 | 2.227 | 2.189 | 2.149 | 2.107 | 2.067 | 2.022 | 2.028 | 2.022 | 2.010 |
| Debts | 4.110.387 | 3.395.946 | 3.338.528 | 3.266.834 | 3.203.581 | 3.142.861 | 3.073.180 | 3.082.730 | 3.073.382 | 2.397.629 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "6820 - 6820" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Varium Parafarmaceutice Srl